Yuan Yuan1, Kathy Pan2, Joanne Mortimer1, Rowan T Chlebowski2, Juhua Luo3, Jessica E Yan2, Susan E Yost1, Candyce H Kroenke4, Lucile Adams-Campbell5, Rami Nassir6, Yangbo Sun7, Aladdin H Shadyab8, Mara Z Vitolins9, Nazmus Saquib10, Robert A Wild11, JoAnn E Manson12, Rebecca A Nelson1. 1. City of Hope National Medical Center, Duarte, California. 2. Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California. 3. University of Indiana, Bloomington, Indiana. 4. Kaiser Permanente, Northern California, Oakland, California. 5. Georgetown University School of Medicine, Washington, DC. 6. Department of Pathology, School of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia. 7. University of Iowa, Iowa City, Iowa. 8. University of California San Diego, La Jolla, California. 9. Wake Forest School of Medicine, Winston Salem, North Carolina. 10. Sulaiman Al Rajhi College of Medicine, Al Bukairiyah, Saudi Arabia. 11. Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 12. Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) has a high recurrence risk and poor clinical outcomes. Associations between metabolic syndrome (MetS) risk components and mortality in postmenopausal women with TNBC were examined in the Women's Health Initiative. METHODS: Five hundred forty-four postmenopausal women were diagnosed with nonmetastatic TNBC. Baseline risk components included a high waist circumference (≥88 cm), high blood pressure, hypercholesterolemia, and diabetes. Groups were categorized by the number of MetS risk components: none, 1 or 2, or 3 or 4. Hazard ratios (HRs) and 95% confidence intervals (CIs) across groups were computed with multivariable adjusted Cox models. Outcomes included breast cancer-specific mortality and breast cancer overall mortality (breast cancer followed by death from any cause). Variables in the multivariable model included age at TNBC diagnosis; race/ethnicity; income; education; clinical/observational trial status; history of oral contraceptive, hormone, and/or statin use; cancer stage; and chemotherapy and/or radiation treatment status. RESULTS: Of the 544 participants with TNBC, 33% had no MetS risk components (n = 178), 59% had 1 or 2 risk components (n = 323), and 8% had 3 or 4 risk components (n = 43). After a median follow-up from diagnosis of 8.3 years, multivariable results showed that women with 3 or 4 risk components had a nonsignificantly higher risk of breast cancer mortality (HR, 2.05; 95% CI, 0.94-4.47 trend P = .114) and a significantly higher risk of overall mortality (HR, 2.13; 95% CI, 1.22-3.71; trend P = .006) versus women with 0 risk components. CONCLUSIONS: Postmenopausal women with TNBC and 3 or 4 MetS risk components have a nonsignificantly higher breast cancer mortality risk and a significantly higher overall mortality risk, likely because of negative influences of metabolic risk factors on several causes of death.
BACKGROUND: Triple-negative breast cancer (TNBC) has a high recurrence risk and poor clinical outcomes. Associations between metabolic syndrome (MetS) risk components and mortality in postmenopausal women with TNBC were examined in the Women's Health Initiative. METHODS: Five hundred forty-four postmenopausal women were diagnosed with nonmetastatic TNBC. Baseline risk components included a high waist circumference (≥88 cm), high blood pressure, hypercholesterolemia, and diabetes. Groups were categorized by the number of MetS risk components: none, 1 or 2, or 3 or 4. Hazard ratios (HRs) and 95% confidence intervals (CIs) across groups were computed with multivariable adjusted Cox models. Outcomes included breast cancer-specific mortality and breast cancer overall mortality (breast cancer followed by death from any cause). Variables in the multivariable model included age at TNBC diagnosis; race/ethnicity; income; education; clinical/observational trial status; history of oral contraceptive, hormone, and/or statin use; cancer stage; and chemotherapy and/or radiation treatment status. RESULTS: Of the 544 participants with TNBC, 33% had no MetS risk components (n = 178), 59% had 1 or 2 risk components (n = 323), and 8% had 3 or 4 risk components (n = 43). After a median follow-up from diagnosis of 8.3 years, multivariable results showed that women with 3 or 4 risk components had a nonsignificantly higher risk of breast cancer mortality (HR, 2.05; 95% CI, 0.94-4.47 trend P = .114) and a significantly higher risk of overall mortality (HR, 2.13; 95% CI, 1.22-3.71; trend P = .006) versus women with 0 risk components. CONCLUSIONS: Postmenopausal women with TNBC and 3 or 4 MetS risk components have a nonsignificantly higher breast cancer mortality risk and a significantly higher overall mortality risk, likely because of negative influences of metabolic risk factors on several causes of death.
Authors: Wambui G Gathirua-Mwangi; Patrick O Monahan; Mwangi J Murage; Jianjun Zhang Journal: Cancer Causes Control Date: 2017-01-17 Impact factor: 2.506
Authors: M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens Journal: Am J Epidemiol Date: 1984-05 Impact factor: 4.897
Authors: Geoffrey C Kabat; Mimi Y Kim; Jennifer S Lee; Gloria Y Ho; Scott B Going; Jennifer Beebe-Dimmer; JoAnn E Manson; Rowan T Chlebowski; Thomas E Rohan Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-09-22 Impact factor: 4.254
Authors: Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger Journal: Cancer Prev Res (Phila) Date: 2012-10-03
Authors: F P Turkoz; M Solak; I Petekkaya; O Keskin; N Kertmen; F Sarici; Z Arik; T Babacan; Y Ozisik; K Altundag Journal: J BUON Date: 2013 Apr-Jun Impact factor: 2.533
Authors: Jody M Jackson; Terese A DeFor; A Lauren Crain; Tessa J Kerby; Lori S Strayer; Cora E Lewis; Evelyn P Whitlock; Selvi B Williams; Mara Z Vitolins; Rebecca J Rodabough; Joseph C Larson; Elizabeth B Habermann; Karen L Margolis Journal: Menopause Date: 2014-08 Impact factor: 2.953
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Gregory S Calip; Kathleen E Malone; Julie R Gralow; Andy Stergachis; Rebecca A Hubbard; Denise M Boudreau Journal: Breast Cancer Res Treat Date: 2014-10-10 Impact factor: 4.872
Authors: Peter M Anderson; Stefanie M Thomas; Shauna Sartoski; Jacob G Scott; Kaitlin Sobilo; Sara Bewley; Laura K Salvador; Maritza Salazar-Abshire Journal: Nutrients Date: 2021-12-08 Impact factor: 5.717